NASDAQ:XOMAXOMA Stock Price, Forecast & News

XOMA's stock was trading at $19.50 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, XOMA shares have increased by 11.5% and is now trading at $21.75. View which stocks have been most impacted by Coronavirus.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for XOMA in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for XOMA.

XOMA is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for XOMA.

XOMA Corp (NASDAQ:XOMA) released its quarterly earnings data on Tuesday, May, 5th. The biotechnology company reported ($0.49) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.16) by $0.33. The biotechnology company had revenue of $0.80 million for the quarter, compared to the consensus estimate of $3.40 million. XOMA had a negative return on equity of 34.27% and a negative net margin of 102.32%. View XOMA's earnings history.

2 brokers have issued twelve-month price targets for XOMA's stock. Their forecasts range from $29.00 to $30.00. On average, they anticipate XOMA's stock price to reach $29.50 in the next twelve months. This suggests a possible upside of 35.6% from the stock's current price. View analysts' price targets for XOMA.

News headlines about XOMA stock have trended neutral on Saturday, InfoTrie reports. InfoTrie rates the sentiment of press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. XOMA earned a media sentiment score of 0.4 on InfoTrie's scale. They also assigned media headlines about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the near term. View the latest news aboutXOMA.

Some companies that are related to XOMA include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Immunomedics (IMMU). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other XOMA investors own include Cytokinetics (CYTK), Alnylam Pharmaceuticals (ALNY), Ascent Solar Technologies (ASTI), CTI BioPharma (CTIC), TransEnterix (TRXC), Opko Health (OPK), Gilead Sciences (GILD), Uranium Energy (UEC), Ekso Bionics (EKSO) and NXP Semiconductors (NXPI).

XOMA trades on the NASDAQ under the ticker symbol "XOMA."

XOMA's stock is owned by a number of retail and institutional investors. Top institutional investors include Stonepine Capital Management LLC (1.89%), BlackRock Inc. (1.78%), Geode Capital Management LLC (0.54%), Cadence Capital Management LLC (0.50%), EAM Investors LLC (0.36%) and Invesco Ltd. (0.29%). Company insiders that own XOMA stock include Bvf Partners L P/Il, James R Neal, Ness W Denman Van, Thomas M Burns and Value Fund L P Biotechnology. View institutional ownership trends for XOMA.

XOMA stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Two Sigma Investments LP, Geode Capital Management LLC, BlackRock Inc., Alps Advisors Inc., First Manhattan Co., and EAM Investors LLC. Company insiders that have sold XOMA company stock in the last year include James R Neal, and Thomas M Burns. View insider buying and selling activity for XOMA.

XOMA stock was bought by a variety of institutional investors in the last quarter, including Cadence Capital Management LLC, Invesco Ltd., Stonepine Capital Management LLC, Wells Fargo & Company MN, and Citigroup Inc.. Company insiders that have bought XOMA stock in the last two years include Bvf Partners L P/Il, James R Neal, and Value Fund L P Biotechnology. View insider buying and selling activity for XOMA.

Shares of XOMA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of XOMA stock can currently be purchased for approximately $21.75.

XOMA has a market capitalization of $239.69 million and generates $18.37 million in revenue each year. The biotechnology company earns $-1,980,000.00 in net income (profit) each year or ($0.23) on an earnings per share basis. XOMA employs 11 workers across the globe.

The official website for XOMA is www.xoma.com.

XOMA's mailing address is 2200 POWELL STREET SUITE 310, EMERYVILLE CA, 94608. The biotechnology company can be reached via phone at 510-204-7200 or via email at [email protected]